Group 1 - The company has decided to terminate the plan for issuing shares to purchase assets and raise supporting funds due to changes in the market environment and the actual situation of Xi'an Zhongke Nuclear Instrument Co., Ltd. since the initial planning of the transaction [1][2] - The decision was made unanimously by the supervisory board, with all three attending members voting in favor of the resolution [1] - The supervisory board emphasized that the termination of the transaction is aimed at protecting the long-term interests of the company and its investors [1]

Core Viewpoint - China Nuclear Technology announced the termination of the transaction to acquire 98.87% of Xi'an China Nuclear Instrument Co., Ltd. due to changes in market conditions and the actual situation of the target company [1][6][10] Group 1: Transaction Details - The planned transaction was expected to constitute a major asset restructuring and related party transaction, aligning with the industry's trend of enhancing competitiveness through mergers and acquisitions [1][6] - The transaction was part of China Nuclear Group's strategy to inject quality assets into its listed companies, with both China Nuclear Technology and Xi'an China Nuclear Instrument being controlled by China Nuclear Group [1][5] - The transaction involved multiple parties, including China Nuclear Power Engineering Co., Ltd. and various investment funds, all under the control of China Nuclear Group [3][5] Group 2: Financial Data - As of September 30, 2024, China Nuclear Technology reported total assets of 2.663 billion yuan and net assets of 1.491 billion yuan [2] - The company's revenue for 2022, 2023, and the first three quarters of 2024 were 1.149 billion yuan, 1.324 billion yuan, and 663 million yuan, respectively, with net profits of 177 million yuan, 164 million yuan, and 81.6 million yuan [1][2] - The total liabilities as of September 30, 2024, were 1.172 billion yuan, with total equity of 1.491 billion yuan [2] Group 3: Strategic Implications - The termination of the transaction is seen as a setback for China Nuclear Technology, which aimed to enhance its strength and core competitiveness in the nuclear equipment manufacturing sector [6][7] - Xi'an China Nuclear Instrument is recognized as a key supplier in the nuclear industry, specializing in radiation monitoring systems and other safety systems, indicating its strong market position [6] - The company had anticipated that the transaction would improve its profitability and investment value, aligning with industry development trends [7]

Core Viewpoint - Several listed companies in the Shanghai and Shenzhen markets have announced significant developments, including management changes, stock trading fluctuations, and major contracts, which may present investment opportunities and risks for investors [2]. Group 1: Management Changes and Legal Issues - Scanda's chairman and general manager, Li Yuejie, along with director Zhu Chuncheng, have been subjected to criminal coercive measures due to alleged violations related to information disclosure [3]. - Longhong High-Tech is planning to acquire 100% equity of Guangxi Changke, leading to a stock suspension for up to 10 trading days [6]. Group 2: Stock Trading and Performance - New Asia Electronics reported abnormal stock trading with a cumulative price deviation exceeding 20% over three days, while confirming that its operations are normal and consistent with previously disclosed share reduction plans [5]. - ST Tiexin announced the removal of risk warnings and a name change, which will increase the trading limit from 5% to 10% [8]. Group 3: Financial Performance Forecasts - Industrial Fulian expects a net profit increase of 36.84% to 39.12% year-on-year for the first half of 2025, driven by a surge in AI-related business [18]. - Huayou Cobalt anticipates a net profit increase of 55.62% to 67.59% for the same period, benefiting from integrated operations and rising cobalt prices [19]. - Guoli Co. forecasts a staggering net profit increase of 130.91% to 158.08% for the first half of 2025, attributed to new product and market expansions [20]. - Bangji Technology expects a net profit increase of 166.77% to 200.91%, driven by increased sales from direct sales channels [21]. - Lier Chemical predicts a net profit increase of 185.24% to 196% due to rising product sales and cost reduction efforts [25]. Group 4: Major Contracts and Projects - Huadian Science and Technology signed significant contracts worth approximately RMB 25.16 billion for coal handling and transportation systems [41]. - Aerospace Engineering is the first candidate for a project with a bid of RMB 23.92 billion for a coal gasification facility [43].

Core Viewpoint - China Nuclear Technology has decided to terminate the major asset restructuring plan due to changes in market conditions and the actual situation of the target company, Xi'an China Nuclear Instrument Co., Ltd. [2][7] Group 1: Company Overview - China Nuclear Technology announced the termination of the transaction to acquire 98.87% of Xi'an China Nuclear Instrument Co., Ltd. and raise matching funds, which was expected to constitute a major asset restructuring and related party transaction [5][7]. - The transaction was part of a strategy by China National Nuclear Corporation (CNNC) to inject quality assets into its listed companies, enhancing competitiveness through mergers and acquisitions [5][6]. Group 2: Financial Data - As of September 30, 2024, China Nuclear Technology reported total assets of 2.663 billion yuan and net assets of 1.491 billion yuan [7]. - The operating revenues for 2022, 2023, and the first three quarters of 2024 were 1.149 billion yuan, 1.324 billion yuan, and 663 million yuan, respectively, with net profits of 177 million yuan, 164 million yuan, and 81.6 million yuan [7][16]. Group 3: Market Environment - The decision to terminate the transaction was influenced by changes in the market environment and the actual conditions of Xi'an China Nuclear Instrument Co., Ltd. since the initial planning of the transaction [7][14]. - The restructuring was seen as a way to strengthen the competitive position of companies in the nuclear industry, which is experiencing a trend towards consolidation among leading firms [18]. Group 4: Strategic Implications - The termination of the transaction means that the expected benefits, such as enhancing core competitiveness in the nuclear equipment manufacturing sector, will not be realized [15][16]. - The planned fundraising was intended to cover transaction-related taxes and fees, support project construction, and improve liquidity for both China Nuclear Technology and Xi'an China Nuclear Instrument Co., Ltd. [13][14]. Group 5: Stock Performance - As of July 7, the stock price of China Nuclear Technology was 21.72 yuan per share, with a total market capitalization of 8.328 billion yuan [19].

综上，本次董事会审议事项符合法律、法规和政策的相关规定以及公司的利益，对公司 及全体股东公平、合理，不存在损害公司及其股东利益的情形，我们同意公司终止本次交易 事项，并同意将相关议案提交公司董事会审议。 本页无正文，为《中核苏阀科技实业股份有限公司独立董事专门会议关于终止发行股份购买 资产并募集配套资金暨关联交易事项的审核意见》之签字页 独立董事签字： 中核苏阀科技实业股份有限公司独立董事专门会议 关于终止发行股份购买资产并募集配套资金暨关联交易事 项的审核意见 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司独立董 事管理办 法》等法律、法规、规范性文件以及《公司章程》等有关规定，中核苏阀科技实业股份有限 公司（以下简称"公司"）独立董事已在公司第八届董事会第十八次会议召开之前，召开独 立董事专门会议，认真审查董事会提供的会议资料，审议通过与本次交易相关的议案。 在审阅有关资料和听取相关汇报后，公司独立董事对公司董事会审议的关于 公司拟通 过发行股份的方式购买西安中核核仪器股份有限公司（以下简称"中核西仪"）股份并募集 配套资金暨关联交易事项（以下简称"本次交易"）的相关议案，发表审核意见如下 ...

股票代码: 000777 公司简称：中核科技 公告编号:2025-046 中核苏阀科技实业股份有限公司关于终止发行股份 购买资产并募集配套资金暨关联交易事项的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 中核苏阀科技实业股份有限公司（以下简称"公司"）于 2025 年 7 月 7 日召开第八届 董事会第十八次会议、第八届监事会第十五次会议，审议通过了《关于终止发行股份购买资 产并募集配套资金暨关联交易事项的议案》，同意公司终止发行股份购买资产并募集配套资 金暨关联交易（以下简称"本次交易"）事项，公司独立董事专门会议审议通过相关议案， 并发表了同意终止本次交易的审核意见。 现将有关事项公告如下： 一、本次交易的基本情况 公司拟以发行股份方式购买中国核电工程有限公司持有的西安中核核仪器股份有限公 司（以下简称 "标的公司"）71.96%股份、国华军民融合产业发展基金（有限合伙）持有 的标的公司 11.21%股份、融核产业发展基金（海盐）合伙企业（有限合伙）持有的标的公司 8.41%股份、华舆正心（天津）股权投资基金合伙企业（有限合伙）持有的标的公司 5. ...

说明会具体安排如下： 一、说明会召开的时间、地点和方式 （一）召开时间：2025 年 7 月 10 日（星期四） 15:00-16:00。 （二）召开方式：网络文字互动方式。 股票代码: 000777 公司简称：中核科技 公告编号:2025-048 关于召开终止发行股份购买资产并募集配套资金 暨关联交易事项投资者说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 中核苏阀科技实业股份有限公司（以下简称"公司"）于 2025 年 7 月 7 日召开第八届 董事会第十八次会议、第八届监事会第十五次会议，审议通过了《关于终止发行股份购买资 产并募集配套资金暨关联交易事项的议案》，同意公司终止发行股份购买资产并募集配套资 金暨关联交易（以下简称"本次交易"）事项，公司独立董事专门会议审议通过相关议案， 并发表了同意终止本次交易的审核意见。具体内容详见公司于 2025 年 7 月 8 日披露的《中 核苏阀科技实业股份有限公司关于终止发行股份购买资产并募集配套资金暨关联交易事项 的公告》（公告编号：2025-046）。 为加强与投资者的沟通和交流，公司将于 20 ...

经与会监事表决，形成以下决议： 审议并通过了《关于终止发行股份购买资产并募集配套资金暨关联交易事项的议案》； 股票代码: 000777 公司简称：中核科技 公告编号:2025-047 中核苏阀科技实业股份有限公司 第八届监事会第十五次会议决议公告 本公司及监事会全体成员保证公告信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或者重大遗漏。 中核苏阀科技实业股份有限公司（以下简称"公司"）第八届监事会第十五次会议于 2025 年 7 月 6 日以书面方式向全体监事发出会议通知，全体监事一致同意豁免本次监事会会议的提前通知期限，会议 于 2025 年 7 月 7 日在公司会议室以现场+视频表决形式召开。 会议由监事会主席谢永辉先生主持。会议应到监事 3 人，实际参会监事 3 人。本次会议的召开符合 《公司法》和《公司章程》的有关规定，会议合法有效。 经审议，同意 3 票，反对 0 票，弃权 0 票，回避 0 票 监事会认为：自本次交易预案披露以来，公司及交易相关方积极推进本次交易的相关工作，公司严 格按照相关法律、法规及规范性文件等规定，组织相关各方积极推进本次交易。公司终止本次交易事项 是综合考虑到当 ...

股票代码: 000777 公司简称：中核科技 公告编号:2025-045 中核苏阀科技实业股份有限公司 第八届董事会第十八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 中核苏阀科技实业股份有限公司（以下简称"公司"）第八届董事会第十八次会议于 2025 年 7 月 6 日以书面方式向全体董事发出会议通知，全体董事一致同意豁免本次董事会 会议的提前通知期限，会议于 2025 年 7 月 7 日在公司会议室以现场+视频表决形式召开。 具体内容详见同日刊登于巨潮资讯网 www.cninfo.com.cn 的《关于终止发行股份购买 资产并募集配套资金暨关联交易事项的公告》（公告编号：2025-046）。 特此公告。 中核苏阀科技实业股份有限公司董事会 二〇二五年七月八日 会议由董事长马瀛先生主持。会议参会董事九人。公司监事会成员及高管列席了本次董 事会。本次会议的召开符合《公司法》和《公司章程》的有关规定，会议合法有效。会议内 容如下： 审议并通过了《关于终止发行股份购买资产并募集配套资金暨关联交易事项的议案》； 经审议，表决结果：同意3票，反对0票 ...

Industry Overview - The Chinese ball valve industry is projected to reach a market size of approximately 29 billion yuan in 2024, with a compound annual growth rate (CAGR) of 4.92% over the past five years [1]. - The ball valve has been developed in China for over 70 years, with significant advancements in long-distance pipeline ball valves and metal-sealed ball valves since the 21st century [1]. Market Trends - The number of bidding projects in the ball valve industry has shown an upward trend, increasing from around 3,000 projects in 2021 to over 8,000 projects expected in 2024 [4]. Competitive Landscape - Key players in the domestic ball valve manufacturing industry include Neway Valve (纽威股份), Fangzheng Valve (方正阀门), Jiangsu Shentong (江苏神通), Yongsheng Technology (永盛科技), Jintai Meilin (金泰美林), and Zhongde Technology (中德科技) [7]. - Neway Valve is noted for having the most comprehensive product offerings and the largest revenue scale, positioning it in the leading tier of the domestic ball valve market [7]. Product Offerings - Neway Valve specializes in floating ball valves, fixed ball valves, and double ball valves [8]. - Jiangsu Shentong offers hard-sealed ball valves, ceramic ball valves, high-temperature and high-pressure ball valves, and various nuclear-grade ball valves [8]. - Zhongde Technology provides a range of ball valves including floating hard-sealed, fixed soft-sealed, and LNG ultra-low temperature ball valves [8]. - Fangzheng Valve focuses on side-mounted, top-mounted, and fully welded ball valves, among others [8]. - Zhejiang Lino offers various types of ball valves including flange V-type ball valves and floating ball valves [8].